MEDINET Co., Ltd. (2370.T)
JPY 37.0
(0.0%)
JPY 37.0
(0.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 2.3 Million JPY | -46.34% |
| 2022 | 4.29 Million JPY | -44.1% |
| 2021 | 7.69 Million JPY | -53.28% |
| 2020 | 16.46 Million JPY | -50.07% |
| 2019 | 32.96 Million JPY | -55.08% |
| 2018 | 73.38 Million JPY | -42.53% |
| 2017 | 127.69 Million JPY | -87.7% |
| 2016 | 1.03 Billion JPY | 3.62% |
| 2015 | 1 Billion JPY | 13.99% |
| 2014 | 878.76 Million JPY | 0.97% |
| 2013 | 870.31 Million JPY | -52.96% |
| 2012 | 1.85 Billion JPY | -0.81% |
| 2011 | 1.86 Billion JPY | 81.77% |
| 2010 | 1.02 Billion JPY | 14580.43% |
| 2009 | 6.99 Million JPY | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q3 | - JPY | -28.04% |
| 2024 Q1 | 91.32 Million JPY | 3858.43% |
| 2024 Q2 | 85.3 Million JPY | -6.58% |
| 2023 Q2 | 94.63 Million JPY | 21.21% |
| 2023 Q3 | 136.23 Million JPY | 43.95% |
| 2023 Q4 | 2.3 Million JPY | -98.31% |
| 2023 Q1 | 78.08 Million JPY | 1716.24% |
| 2023 FY | 2.3 Million JPY | -46.34% |
| 2022 Q1 | 63.4 Million JPY | 724.55% |
| 2022 FY | 4.29 Million JPY | -44.1% |
| 2022 Q4 | 4.29 Million JPY | -96.05% |
| 2022 Q3 | 108.7 Million JPY | -56.35% |
| 2022 Q2 | 249.05 Million JPY | 292.78% |
| 2021 Q1 | - JPY | -100.0% |
| 2021 FY | 7.69 Million JPY | -53.28% |
| 2021 Q4 | 7.69 Million JPY | -89.63% |
| 2021 Q3 | 74.18 Million JPY | 27.51% |
| 2021 Q2 | 58.17 Million JPY | 0.0% |
| 2020 Q4 | 16.46 Million JPY | 0.0% |
| 2020 FY | 16.46 Million JPY | -50.07% |
| 2020 Q2 | - JPY | 0.0% |
| 2020 Q3 | - JPY | 0.0% |
| 2020 Q1 | - JPY | -100.0% |
| 2019 Q1 | - JPY | -100.0% |
| 2019 Q4 | 32.96 Million JPY | 0.0% |
| 2019 Q3 | - JPY | 0.0% |
| 2019 Q2 | - JPY | 0.0% |
| 2019 FY | 32.96 Million JPY | -55.08% |
| 2018 Q4 | 73.38 Million JPY | 0.0% |
| 2018 Q3 | - JPY | -100.0% |
| 2018 Q2 | 75 Million JPY | 0.0% |
| 2018 Q1 | - JPY | -100.0% |
| 2018 FY | 73.38 Million JPY | -42.53% |
| 2017 Q4 | 127.69 Million JPY | -87.07% |
| 2017 Q2 | 875 Million JPY | 0.0% |
| 2017 Q3 | 987.5 Million JPY | 12.86% |
| 2017 FY | 127.69 Million JPY | -87.7% |
| 2017 Q1 | 875 Million JPY | -15.7% |
| 2016 Q1 | 1.3 Billion JPY | 29.78% |
| 2016 Q2 | 1.3 Billion JPY | 0.0% |
| 2016 Q3 | 875 Million JPY | -32.69% |
| 2016 Q4 | 1.03 Billion JPY | 18.63% |
| 2016 FY | 1.03 Billion JPY | 3.62% |
| 2015 FY | 1 Billion JPY | 13.99% |
| 2015 Q2 | 800 Million JPY | 0.0% |
| 2015 Q1 | 800 Million JPY | -8.96% |
| 2015 Q4 | 1 Billion JPY | 25.21% |
| 2015 Q3 | 800 Million JPY | 0.0% |
| 2014 Q3 | 800 Million JPY | 0.0% |
| 2014 Q2 | 800 Million JPY | 0.0% |
| 2014 Q1 | 800 Million JPY | -8.08% |
| 2014 FY | 878.76 Million JPY | 0.97% |
| 2014 Q4 | 878.76 Million JPY | 9.85% |
| 2013 Q2 | 800 Million JPY | -55.56% |
| 2013 Q3 | 800 Million JPY | 0.0% |
| 2013 Q4 | 870.31 Million JPY | 8.79% |
| 2013 FY | 870.31 Million JPY | -52.96% |
| 2013 Q1 | 1.8 Billion JPY | -2.71% |
| 2012 Q3 | 1.8 Billion JPY | 0.0% |
| 2012 Q4 | 1.85 Billion JPY | 2.79% |
| 2012 FY | 1.85 Billion JPY | -0.81% |
| 2012 Q1 | 1.8 Billion JPY | -3.5% |
| 2012 Q2 | 1.8 Billion JPY | 0.0% |
| 2011 FY | 1.86 Billion JPY | 81.77% |
| 2011 Q1 | 1.5 Billion JPY | 46.18% |
| 2011 Q2 | 1.8 Billion JPY | 20.0% |
| 2011 Q3 | 1.7 Billion JPY | -5.56% |
| 2011 Q4 | 1.86 Billion JPY | 9.72% |
| 2010 Q1 | - JPY | -100.0% |
| 2010 Q2 | - JPY | 0.0% |
| 2010 FY | 1.02 Billion JPY | 14580.43% |
| 2010 Q4 | 1.02 Billion JPY | 2.62% |
| 2010 Q3 | 1 Billion JPY | 0.0% |
| 2009 FY | 6.99 Million JPY | 0.0% |
| 2009 Q2 | - JPY | 0.0% |
| 2009 Q4 | 6.99 Million JPY | 0.0% |
| 2009 Q1 | - JPY | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 2.46 Billion JPY | 99.907% |
| PRISM BioLab Co.,LTD | - JPY | -Infinity% |
| GNI Group Ltd. | 3.69 Billion JPY | 99.938% |
| Linical Co., Ltd. | 3 Billion JPY | 99.923% |
| Trans Genic Inc. | 2.25 Billion JPY | 99.898% |
| Soiken Holdings Inc. | - JPY | -Infinity% |
| Cytori Cell Research Institute, Inc. | 2.47 Billion JPY | 99.907% |
| AnGes, Inc. | 362.67 Million JPY | 99.364% |
| OncoTherapy Science, Inc. | 106.84 Million JPY | 97.841% |
| Nxera Pharma Co., Ltd. | 73.97 Billion JPY | 99.997% |
| Immuno-Biological Laboratories Co., Ltd. | 235.98 Million JPY | 99.022% |
| NanoCarrier Co., Ltd. | 1.1 Billion JPY | 99.792% |
| Carna Biosciences, Inc. | 182.97 Million JPY | 98.739% |
| CanBas Co., Ltd. | - JPY | -Infinity% |
| D. Western Therapeutics Institute, Inc. | 885.12 Million JPY | 99.739% |
| RaQualia Pharma Inc. | 367.71 Million JPY | 99.373% |
| Chiome Bioscience Inc. | 291 Million JPY | 99.207% |
| Kidswell Bio Corporation | 2.57 Billion JPY | 99.91% |
| PeptiDream Inc. | 22.79 Billion JPY | 99.99% |
| Oncolys BioPharma Inc. | 315.17 Million JPY | 99.268% |
| Ribomic Inc. | - JPY | -Infinity% |
| SanBio Company Limited | 665 Million JPY | 99.653% |
| Healios K.K. | 4.53 Billion JPY | 99.949% |
| BrightPath Biotherapeutics Co., Ltd. | 112.5 Million JPY | 97.949% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 142.85 Million JPY | 98.385% |
| Delta-Fly Pharma, Inc. | - JPY | -Infinity% |
| StemRIM | - JPY | -Infinity% |
| CellSource Co., Ltd. | 97.54 Million JPY | 97.635% |
| FunPep Company Limited | - JPY | -Infinity% |
| Kringle Pharma, Inc. | - JPY | -Infinity% |
| Stella Pharma Corporation | 933.3 Million JPY | 99.753% |
| TMS Co., Ltd. | - JPY | -Infinity% |
| Noile-Immune Biotech Inc. | - JPY | -Infinity% |
| Cuorips Inc. | - JPY | -Infinity% |
| K Pharma,Inc. | - JPY | -Infinity% |
| Takara Bio Inc. | 968 Million JPY | 99.762% |
| ReproCELL Incorporated | - JPY | -Infinity% |
| PhoenixBio Co., Ltd. | 723.93 Million JPY | 99.681% |
| StemCell Institute Inc. | 8.78 Million JPY | 73.736% |
| Japan Tissue Engineering Co., Ltd. | - JPY | -Infinity% |
| CellSeed Inc. | 151.25 Million JPY | 98.475% |